Startups
Alimera Sciences, Inc. (NASDAQ: ALIM) (“Alimera”), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Our lead product is ILUVIEN, now approved for marketing in the U.S. and 15 European countries for the treatment of diabetic macular edema.
Overview
Location
United States, Georgia, Alpharetta
Employees
201-500
Phone
+1 678-990-5740
Founded date
2003
Investors 4
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Aug 7, 2021 | New Enterprise Associates | nea.com |
| Nov 6, 2022 | Hercules Capital | htgc.com |
| Sofinnova Investments | sofinnova.com |
Mentions in press and media 14
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jul 31, 2024 | Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes | In the world of finance, numbers tell stories. They pulse with the rhythm of market dynamics, reflecting the health of companies and the sentiments of investors. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, re... |
| Jul 26, 2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders | NEW YORK, July 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| Mar 7, 2024 | Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results | |
| Jun 2, 2022 | Alimera Sciences to Present at the LD Micro Invitational XII Conference | ATLANTA, June 02, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintain... |
| Apr 14, 2021 | Alimera Sciences, Inc. announced that it has received $10 million in funding from Ocumension Therapeutics | Alimera Sciences, Inc. (NasdaqGM:ALIM) announced that it has entered into a share purchase agreement for a private placement of 1,144,945 common shares, par value $0.01 per share, at a purchase price of $8.734044 per share for gross proceed... |
| Apr 14, 2021 | ALIMERA SCIENCES, INC. Alimera Sciences : Receives $20 Million From Ocumension Therapeutics | Alimera grants exclusive license to Ocumension for a $10 million upfront payment and up to $89 million in additional sales-based milestone payments Ocumension makes a $10 million equity investment in Alimera ATLANTA, April 14, 2021 (GLOBE N... |
| Feb 18, 2014 | Alimera raises $37.5M in private placement | Alimera Sciences (NSDQ:ALIM) raised $37.5 million in a recent funding round, planning on using the funds to support general corporate operations. The Atlanta, Ga.-based device maker sold about 6.3 million newly issued shares of common stock... |
| Oct 3, 2012 | Biotech company developing therapies for macular edema raises $40 million | Solution/Product: The company makes the Iluvien drug delivery system that is implanted at the back of the eye and is designed to release sub-microgram levels of fluocinolone acetonide for up to 36 months to treat chronic diabetic macular ed... |
| Apr 23, 2010 | Morning Read: Americans more confused than angry over health reform | Why people hate insurance companies: Reuters has a stunning story about Wellpoint, the nation’s largest insurer, and its policy to rescind insurance from women suffering from breast cancer. It’s difficult to do justice to this lengthy, leng... |
Show more
Reviews 0
FAQ about Alimera Sciences
When was Alimera Sciences founded?
Alimera Sciences was founded in 2003.
Who has invested in Alimera Sciences?
Parsers VC lists 4 investors of Alimera Sciences, among them Hercules Capital, New Enterprise Associates and Sofinnova Investments.
What has the press written about Alimera Sciences?
Parsers VC has collected 14 articles mentioning Alimera Sciences, among them “Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes” (Jul 31, 2024) and “SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders” (Jul 26, 2024).
Is Alimera Sciences still active?
Yes, Alimera Sciences is active; its latest activity on Parsers VC dates from Aug 20, 2024.